Animal Model Market

Emerging markets are increasingly contributing to the Global Animal Model Market Industry as globalization facilitates collaboration and knowledge exchange. Countries in Asia-Pacific and Latin America are witnessing a rise in research activities, driven by both local and international investments. This trend is fostering the development of regional animal model facilities and research institutions, which are essential for advancing scientific knowledge. The expansion of these markets is expected to enhance the overall growth of the industry, as they adopt advanced animal models for research purposes. The globalization of research initiatives is likely to create new opportunities for market players.

Advancements in genetic engineering techniques, such as CRISPR and gene editing, are significantly influencing the Global Animal Model Market Industry. These technologies enable the creation of more precise and relevant animal models that closely mimic human diseases. This precision enhances the predictability of drug responses, thereby improving the efficiency of preclinical trials. As a result, researchers are increasingly adopting these advanced models, which are expected to drive market growth. The integration of genetically modified organisms into research protocols is likely to contribute to the overall expansion of the market, aligning with the projected growth trajectory leading to 2035.

The increasing demand for biopharmaceuticals is a primary driver of the Global Animal Model Market Industry. As the biopharmaceutical sector expands, the need for effective preclinical testing using animal models becomes crucial. In 2024, the market is valued at approximately 2.79 USD Billion, reflecting the industry's reliance on animal models for drug development and safety assessments. This trend is expected to continue, with projections indicating a market growth to 5.93 USD Billion by 2035. The compound annual growth rate (CAGR) of 7.11% from 2025 to 2035 underscores the importance of animal models in facilitating the development of innovative therapies.

Regulatory support for animal research plays a pivotal role in the Global Animal Model Market Industry. Governments and regulatory bodies are increasingly recognizing the necessity of animal models in the drug development process. This support manifests through guidelines that promote ethical research practices while ensuring the welfare of animals used in studies. Such frameworks facilitate the approval of new drugs and therapies, thereby fostering innovation. As the market evolves, the alignment of regulatory policies with scientific advancements is likely to enhance the credibility and acceptance of animal models, further driving market growth through 2035.

The surge in investment in research and development (R&D) across various sectors is a significant driver of the Global Animal Model Market Industry. Pharmaceutical and biotechnology companies are allocating substantial resources to R&D to discover new therapies and treatments. This trend is reflected in the growing number of preclinical studies utilizing animal models, which are essential for understanding disease mechanisms and testing drug efficacy. The anticipated growth of the market from 2.79 USD Billion in 2024 to 5.93 USD Billion by 2035 highlights the critical role of R&D investments in shaping the future landscape of animal model applications.

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. North America Animal Model market accounted for USD 0.90 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. It is anticipated that the COVID-19 pandemic will result in a swift expansion of the pharmaceutical industry, raising demand for pharmaceuticals, vaccines, and monoclonal antibodies in the region's nations and propelling market revenue growth.

Further, the major countries studied in the market report are: The U.S., Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: ANIMAL MODEL MARKET SHARE BY REGION 2023 (%) 

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe animal model market accounts for the second-largest market share. The region's substantial concentration of toxicological, nutritional, immunological, and other medical labs is anticipated to fuel market revenue growth. Further, the Germany animal model market held the largest market share, and the UK animal model market was the fastest-growing market in the European region.

The Asia-Pacific Animal Model Market is expected to grow at the fastest CAGR from 2022 to 2030. Animal model market revenue is growing due to characteristics such as ease of manipulation, short lifespan, and high reproducibility being adopted in industries across Asia-Pacific. Moreover, the China animal model market held the largest market share, and the India animal model market was the fastest-growing market in the Asia-Pacific region.

Animal Model Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the animal model market grow even more. Market participants are also taking various strategic initiatives to grow their footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the animal model industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies manufacturers adopt in the animal model industry to benefit clients and expand the market sector is manufacturing locally to reduce operating costs. In recent years, the animal model industry has provided some of the most significant benefits. The animal model market major players, such as Horizon Discovery Group plc, Charles River Laboratories International Inc., Transposagen Biopharmaceuticals Inc., and others, are working on expanding the market demand by investing in research and development activities.

Charles River Laboratories International, Inc. specializes in a range of preclinical and clinical laboratory, gene therapy, and cell therapy services for the pharmaceutical, medical device, and biotechnology industries. In May 2021, a gene therapy contract development and manufacturing organization (CDMO), Vigene Biosciences, was purchased by Charles River for $292.5 million.

Also, Envigo is a privately held contract research organization and lab animal source that offers live animals and related goods and services to the biotechnology and pharmaceutical industries, as well as to the government, the academic community, and other life science organizations that use animals in testing. In December 2019, the research models division of Horizon Discovery, which offers genetically altered models from its Boyertown, Pennsylvania, and St. Louis, Missouri, facilities, was bought by Envigo.

Key Companies in the animal model market include

• Horizon Discovery Group plc
• Charles River Laboratories International Inc.
• Transposagen Biopharmaceuticals Inc.
• Trans Genic Inc
• Envigo CRS SA
• Eurofins Scientific SE
• Crown Bioscience Inc.
• The Jackson Laboratory
• Genoway SA, among others

Animal Model Industry Developments

• Q2 2024: Charles River Laboratories Announces Opening of New Preclinical Research Facility in North Carolina Charles River Laboratories opened a new state-of-the-art preclinical research facility in North Carolina to expand its capacity for animal model-based drug development and testing.
• Q1 2024: GenOway and Merck KGaA Announce Strategic Partnership to Develop Next-Generation Humanized Mouse Models GenOway entered a strategic partnership with Merck KGaA to co-develop advanced humanized mouse models for immuno-oncology and autoimmune disease research.
• Q2 2024: Taconic Biosciences Launches New CRISPR-Engineered Rat Model for Neurological Disease Research Taconic Biosciences launched a new CRISPR-engineered rat model designed to accelerate preclinical studies in neurological disorders.
• Q3 2024: Eurofins Scientific Expands Animal Model Services with Acquisition of Preclinical CRO in Japan Eurofins Scientific acquired a leading Japanese preclinical contract research organization to strengthen its animal model services and global reach.
• Q2 2024: The Jackson Laboratory Receives NIH Grant to Develop Rare Disease Mouse Models The Jackson Laboratory was awarded a multi-million dollar NIH grant to develop and distribute new mouse models for rare genetic diseases.
• Q1 2025: Envigo Appoints New CEO to Lead Global Expansion in Animal Model Research Envigo announced the appointment of a new CEO to drive its global expansion and innovation in animal model research services.
• Q2 2025: Charles River Laboratories Acquires Hera BioLabs to Expand Portfolio of Gene-Edited Animal Models Charles River Laboratories acquired Hera BioLabs, enhancing its portfolio of gene-edited animal models for drug discovery and safety testing.
• Q1 2024: Biocytogen Raises $60 Million in Series C Funding to Accelerate Development of Humanized Animal Models Biocytogen secured $60 million in Series C funding to expand its pipeline of humanized animal models for pharmaceutical research.
• Q3 2024: JSR Corporation Announces Strategic Investment in Ozgene to Advance Genetically Modified Animal Model Technologies JSR Corporation made a strategic investment in Ozgene to support the development of next-generation genetically modified animal models.
• Q2 2025: PerkinElmer Launches New Zebrafish Model Platform for High-Throughput Drug Screening PerkinElmer introduced a new zebrafish model platform aimed at enabling high-throughput drug screening for early-stage pharmaceutical research.
• Q1 2025: Trans Genic Inc. Wins Major Contract to Supply Custom Animal Models for European Biotech Consortium Trans Genic Inc. secured a significant contract to supply custom animal models to a consortium of European biotech firms for collaborative research projects.
• Q2 2024: Envigo Opens New Animal Model Production Facility in Germany Envigo opened a new production facility in Germany to meet growing demand for specialized animal models in European biomedical research.

Animal Model Market Segmentation

Animal Model Animal Type Outlook

• Pigs
• Cats
• Mice

Animal Model Technology Outlook

• CRISPR
• Microinjection
• Embryonic Stem Cell Injection

Animal Model Application Outlook

• Research and Development
• Production
• Quality Control

Animal Model End User Outlook

• Research Institutes
• Educational Institutes
• Pharmaceutical Companies
• Contract Research Organizations

Animal Model Regional Outlook

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe

• Asia-Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Australia

  • Rest of Asia-Pacific

• Rest of the World

  • Middle East

  • Africa

  • Latin America

Major market players are spending a lot of money on R&D to increase their product lines, which will help the animal model market grow even more. Market participants are also taking various strategic initiatives to grow their footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the animal model industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies manufacturers adopt in the animal model industry to benefit clients and expand the market sector is manufacturing locally to reduce operating costs. In recent years, the animal model industry has provided some of the most significant benefits. The animal model market major players, such as Horizon Discovery Group plc, Charles River Laboratories International Inc., Transposagen Biopharmaceuticals Inc., and others, are working on expanding the market demand by investing in research and development activities.

Charles River Laboratories International, Inc. specializes in a range of preclinical and clinical laboratory, gene therapy, and cell therapy services for the pharmaceutical, medical device, and biotechnology industries. In May 2021, a gene therapy contract development and manufacturing organization (CDMO), Vigene Biosciences, was purchased by Charles River for $292.5 million.

Also, Envigo is a privately held contract research organization and lab animal source that offers live animals and related goods and services to the biotechnology and pharmaceutical industries, as well as to the government, the academic community, and other life science organizations that use animals in testing. In December 2019, the research models division of Horizon Discovery, which offers genetically altered models from its Boyertown, Pennsylvania, and St. Louis, Missouri, facilities, was bought by Envigo.